{"id":6740,"date":"2011-11-01T09:57:42","date_gmt":"2011-11-01T13:57:42","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=6740"},"modified":"2011-11-01T09:57:42","modified_gmt":"2011-11-01T13:57:42","slug":"u-s-biotech-licenses-hong-kong-university-flu-research","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=6740","title":{"rendered":"U.S. Biotech Licenses Hong Kong University Flu Research"},"content":{"rendered":"<figure id=\"attachment_3844\" aria-describedby=\"caption-attachment-3844\" style=\"width: 250px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/04\/H1N1_DanHigginsCDC.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-3844\" title=\"H1N1_DanHigginsCDC\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/04\/H1N1_DanHigginsCDC.jpg\" alt=\"Influenza ultrastructure illustration (Dan Higgins, CDC)\" width=\"250\" height=\"250\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/04\/H1N1_DanHigginsCDC.jpg 250w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/04\/H1N1_DanHigginsCDC-150x150.jpg 150w\" sizes=\"auto, (max-width: 250px) 100vw, 250px\" \/><\/a><figcaption id=\"caption-attachment-3844\" class=\"wp-caption-text\">Influenza ultrastructure illustration (Dan Higgins, CDC)<\/figcaption><\/figure>\n<p><a href=\"http:\/\/www.aliosbiopharma.com\/index.php\/alios\/press_releases\/82\">Alios BioPharma<\/a> in South San Francisco and University of Hong Kong agreed to a licensing agreement for the university&#8217;s research findings that target influenza viruses. The agreement, officially with the university&#8217;s technology transfer company, will be used to advance the company&#8217;s R&amp;D and commercialization of medicines to treat influenza infection.<\/p>\n<p>The company also agreed to sponsor research by the University of Hong Kong&#8217;s professor of microbiology <a href=\"http:\/\/www0.hku.hk\/mibpage\/staff\/staff_hp\/Dr_Richard_Kao.html\">Richard Kao<\/a>. Kao\u2019s research focuses on the application of chemical genetics in infectious diseases. His work on the <a href=\"http:\/\/www.time.com\/time\/magazine\/article\/0,9171,702205,00.html\">Severe Acute Respiratory Syndrome<\/a> (SARS) virus established the first model of chemical genetics in virology and showed that approach could probe many targets of a pathogenic virus.<\/p>\n<p>In more recent work, Kao applied the chemical genetics model to the <a href=\"http:\/\/www.voanews.com\/english\/news\/asia\/Hong-Kong-Scientists-Find-New-Way-to-Fight-Flu-Viruses-99127654.html\">influenza A virus<\/a>. This research led to the discovery of a nucleoprotein target for the disease and the compound nucleozin as a antagonist of the nucleoprotein. Nucleozin pulls together nucleoproteins from the flu virus, preventing them from infecting a healthy cell&#8217;s nucleus.<\/p>\n<p>Annual flu epidemics, according to the <a href=\"http:\/\/www.who.int\/mediacentre\/factsheets\/2003\/fs211\/en\/\">World Health Organization<\/a>, affect 5 to 15 percent of the population, usually with upper respiratory tract infections. Hospitalization and deaths mainly occur in high-risk groups, such as the elderly and chronically ill. The disease spreads rapidly worldwide, burdening hospitals and reducing economic productivity. In the U.S., the economic toll is estimated at $71 to $167 billion per year.<\/p>\n<p>Read more: <a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=5577\">New Technology Found to Treat Broad Range of Viruses<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alios BioPharma in South San Francisco and University of Hong Kong agreed to a licensing agreement for the university&#8217;s research findings that target influenza viruses. The agreement, officially with the university&#8217;s technology transfer company, will be used to advance the company&#8217;s R&amp;D and commercialization of medicines to treat influenza infection. The company also agreed to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,16],"tags":[107,31,21,97,84,27,26],"class_list":["post-6740","post","type-post","status-publish","format-standard","hentry","category-i-p","category-ventures","tag-asia","tag-biomedical","tag-biotech","tag-china","tag-licensing","tag-pharmaceuticals","tag-university"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/6740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6740"}],"version-history":[{"count":6,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/6740\/revisions"}],"predecessor-version":[{"id":6746,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/6740\/revisions\/6746"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}